




Agency for Toxic Substances and Disease Registry
 












Mention of company name or product does not constitute endorsement
 












1.1   
1
 
1. PUBLIC HEALTH STATEMENT
 
WHAT IS BIS(CHLOROMETHYL) ETHER?
 
Bis(chloromethy1) ether (BCME) is a man-made chemical with a
 
strong, unpleasant odor. It is a clear liquid at room temperature, but
 
it readily evaporates into air. BCME undergoes chemical reactions
 
easily, so it is broken down very rapidly when it comes into contact
 
with water. Consequently, any BCME that might escape from a chemical
 
plant or a chemical waste site into water or moist soil would be
 
destroyed within a few minutes. BCME that escapes into air is also
 




BCME was used in the past to make several types of polymers,
 
resins and textiles. However, because BCME is believed to cause cancer
 
in humans, these uses have been stopped. BCME is now used only in small
 
amounts inside fully enclosed systems in chemical plants. More
 




1.2 HOW MIGHT I BE EXPOSED TO BIS(CHLOROMETHYL)ETHER?
 
Since BCME has such limited use in the United States, chances for
 
exposure to BCME are low. Some BCME can form as an impurity during the
 
production of other chemicals, so exposure might occur in chemical
 
plants that make or use these chemicals. Also, some BCME may exist in
 
chemical waste sites, although this is not certain. Because BCME
 
evaporates easily, the most likely way to be exposed to BCME in the
 
workplace or around a waste site is by breathing air containing BCME
 




More information on possible ways that people can be exposed to
 
BCME is presented in Chapter 5.
 
1.3 HOW CAN BIS(CHLOROMETHYL) ETHER ENTER AND LEAVE MY BODY?
 
Because BCME is so quickly broken down by water, most BCME that
 
contacts the body is quickly changed into other chemicals (formaldehyde
 
and hydrochloric acid) before it passes through the outermost layer of
 
cells contacted (e.g., the cells that line the nose, windpipe and
 
lungs). Some BCME may enter into the blood or internal tissues, but
 




1. PUBLIC HEALTH STATEMENT
 
More information on how BCME enters the body is presented in Chapter 2.
 
1.4 	HOW CAN BIS(CHLOROMETHYL) ETHER AFFECT MY HEALTH?
 
Studies of people exposed to BCME in the workplace show that
 
breathing of BCME vapors causes irritation to the nose, throat, and
 
lungs. Contact with the liquid is also highly irritating to skin. In
 
animals, breathing in high levels of BCME causes swelling and bleeding
 
in the lung and can cause death. Workers exposed to BCME have been
 
shown to have a higher-than-expected incidence of lung cancer. This
 
observation is supported by studies in animals which also show that
 
BCME can cause cancer. More information on the harmful effects of BCME
 
is presented in Chapter 2.
 




Because BCME is broken down so rapidly in the body, there are no
 
specific tests to determine if a human has been exposed to this
 
compound. The only available medical tests are physical examination of
 
the nose and throat, chest X-ray, and examination of the sputum for
 
abnormal cell types. Unfortunately, these tests are not specific for
 
this compound, and would reveal effects of the compound only after
 
damage to the tissues had already occurred. More information on ways to
 
measure BCME is provided in Chapter 6.
 
1.6  WHAT LEVELS OF EXPOSURE HAVE RESULTED IN HARMFUL HEALTH EFFECTS?
 
Tables l-1 through 1-4 show the relationship between exposure to
 
BCME and known health effects besides cancer. Chapter 2 provides
 
information on levels that have been shown to cause cancer in animals.
 
Although no direct information is available from studies in
 
humans, a Minimal Risk Level (MRL) is included in Table l-l., This MRL
 
was derived from animal data for long-term exposure, as described in
 
Chapter 2 and in Table 2-1. The MRL provides a basis for comparison
 
with levels that people might encounter in the air or in food or
 
drinking water. If a person is exposed to BCME at an amount below the
 
MRL, it is not expected that harmful noncancer health effects will
 








1. PUBLIC HEALTH STATEMENT
 
available, some uncertainty is always associated with it. Also, because
 
the method for deriving MRLs does not use any information about cancer,
 




No information exists for either animals or humans on toxic
 
effects following oral exposure (Tables l-3 and l-4), but oral exposure
 
is of little concern since BCME breaks down in water or moist foods and
 
exposure is not likely by this route. Direct skin contact with even
 
small amounts (less than a drop) of the liquid form of BCME causes
 
severe skin irritation at the site of contact. Further information on
 
the exposure levels that have been found to cause harmful health
 








The government has taken a series of steps to reduce the risk of
 
human exposure to BCME. The Occupational Safety and Health
 
Administration (OSHA) regulates BCME as a potential human carcinogen.
 
An average concentration of 1 part per billion (ppb) is considered to
 
be the highest acceptable level in the workplace, and strict controls
 
have been established to minimize exposure to this compound. The U.S.
 
Environmental Protection Agency (EPA) has developed standards which
 
limit the amount of this compound that can be discharged into water or
 
air or disposed of at waste sites, Further information on regulations
 
concerning BCME is provided in Chapter 7.
 
1.8  WHERE CAN I GET MORE INFORMATION?
 
If you have further questions or concerns, please contact your
 
State Health or Environmental Department or:
 















This chapter contains descriptions and evaluations of studies and
 
interpretation of data on the health effects associated with exposure
 
to BCME. Its purpose is to present levels of significant exposure for
 
BCME based on toxicological studies, epidemiological investigations,
 
and environmental exposure data. This information is presented to
 
provide public health officials, physicians, toxicologists, and other
 
interested individuals and groups with (1) an overall perspective of
 
the toxicology of BCME and (2) a depiction of significant exposure
 
levels associated with various adverse health effects.
 
2.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
 
To help public health professionals address the needs of persons
 
living or working near hazardous waste sites, the data in this section
 
are organized first by route of exposure--inhalation, oral, and dermal­
- and then by health effect--death, systemic, immunological,
 
neurological, developmental, reproductive, genotoxic, and carcinogenic
 
effects. These data are discussed in terms of three exposure periods-­
acute, intermediate, and chronic.
 
Levels of significant exposure for each exposure route and
 
duration (for which data exist) are presented in tables and illustrated
 
in figures. The points in the figures showing no-observed-adverse­
effect levels (NOAELS) or lowest-observed-adverse-effect levels
 
(LOAELs) reflect the actual doses (levels of exposure) used in the
 
studies. LOAELs have been classified into "less serious" or "serious"
 
effects. These distinctions are intended to help the users of the
 
document identify the levels of exposure at which adverse health
 
effects start to appear, determine whether or not the intensity of the
 
effects varies with dose and/or duration, and place into perspective
 
the possible significance of these effects to human health.
 
The significance of the exposure levels shown on the tables and
 
graphs may differ depending on the user's perspective. For example,
 
physicians concerned with the interpretation of clinical findings in
 
exposed persons or with the identification of persons with the
 
potential to develop such disease may be interested in levels of
 
exposure associated with "serious" effects. Public health officials and
 
project managers concerned with response actions at Superfund sites may
 









humans or animals (LOAEL) or exposure levels below which no adverse
 
effects (NOAEL) have been observed. Estimates of levels posing minimal
 
risk to humans (minimal risk levels, MRLs) are of interest to health
 
professionals and citizens alike.
 
For certain chemicals, levels of exposure associated with
 
carcinogenic effects may be indicated in the figures. These levels
 
reflect the actual doses associated with the tumor incidences reported
 
in the studies cited. Because cancer effects could occur at lower
 
exposure levels, the figures also show estimated excess risks, ranging
 




Estimates of exposure levels posing minimal risk to humans (MELs)
 
have been made, where data were believed reliable, for the most
 
sensitive noncancer end point for each exposure duration. MRLs include
 
adjustments to reflect human variability and, where appropriate, the
 
uncertainty of extrapolating from laboratory animal data to humans.
 
Although methods have been established to derive these levels (Barnes
 




2.2.1  Inhalation Exposure
 
A number of cases of inhalation exposure of humans to BCME have
 
occurred in the workplace. However, data on BCME concentrations in
 
workplace air are rarely available, and exposure to BCME often occurs
 
in conjunction with exposure to other chemicals, particularly
 
chloromethyl methyl ether (CME). Consequently, there are no reliable
 
dose-response data in humans. The effects of inhalation of BCME have
 
been investigated in animals, with principal emphasis on carcinogenic
 
effects. Available data on the health effects of inhalation of BCME are
 




No reports of acute human lethality due to inhalation of BCME were
 
located. Increased mortality from cancer has been observed in humans
 











In rats, the acute inhalation LC50 for a 7-hour exposure has been
 
estimated to be 7 ppm (Drew et al. 1975). The cause of death was acute
 
lung irritation that resulted in congestion, edema and hemorrhage. A
 
similar LC50 of 5.3 ppm for a 6-hour exposure was estimated in mice
 
(Leong et al. 1971). A single 7-hr exposure to 0.7 ppm did not cause
 
acute or delayed mortality in rats or hamsters, but a single exposure
 
to 2.1 ppm lead to marked reduction in life span in both species (Drew
 
et al. 1975). Repeated exposures (6 hr/d) to 1 ppm lead to a duration
 
dependent increase in mortality. In rats, 3 exposures to 1 ppm lead to
 
50% mortality after about 20 weeks, and 10 exposures lead to 100%
 
mortality within 10 weeks. In hamsters, 3 exposures caused 50%
 
mortality after about one year, and 30 exposures caused 100% mortality
 
within about 10 weeks (Drew et al. 1975). The data on lethality
 
following three exposures to 1 ppm have been presented in Table 1-2.
 
Exposure to as little as 0.1 ppm caused increased mortality in rats
 
when exposure was extended to six months (Leong et al. 1981), primarily
 
because of the occurrence of nasal tumors (see Section 2.2.1.7, below).
 
The highest NOAEL values and all reliable LOAEL values for death
 
in each species and duration category are recorded in Table 2-1 and
 




Respiratory Effects. As noted above, BCME is acutely irritating to
 
the lungs, causing congestion, edema and hemorrhage in rats and
 
hamsters at exposure levels of 0.7 ppm and higher (Drew et al. 1975).
 
This value has been presented in Table 1-2.
 
Exposure of mice to BCME at 1.0 ppm (6 hr/d, 5 d/wk) for 82 days
 
caused marked respiratory distress (Leong et al. 1971), while exposure
 
of rats to 0.1 ppm (6 hr/d, 5 d/wk) for six months did not result in
 
edema, hemorrhage or any effects on the histological appearance of the
 
lung (Leong et al. 1981). The value of 0.1 ppm has been used to
 
calculate the intermediate inhalation MRL value of 0.0003 ppm, as shown
 
in Figure 2-1 and described in the footnote in Table 2-1. This value
 
has also been presented in Table 1-1.
 
In humans, exposure to vapors of chloromethyl methyl ether (CME)
 
containing BCME as a contaminant lead to increased incidence of chronic
 






(Weiss and Boucot 1975; Weiss 1976). Since CME is itself a lung
 
irritant, it is not possible to determine the degree to which BCME may
 
have contributed to the observed respiratory effects.
 
The highest NOAEL values and all reliable LOAEL values for
 
respiratory effects in each species and duration category are recorded
 
in Table 2-1 and plotted in Figure 2-l.
 
Other Systemic Effects. Systemic effects other than on the lungs
 
have not been observed following inhalation exposure to BCME. Leong et
 
al. (1981) observed no effects on cardiovascular, hematological,
 
gastrointestinal, musculoskeletal, endocrine and subcutaneous tissues
 
in rats exposed to 0.1 ppm for six months (6 hr/day, 5 days/week). This
 
is consistent with the hypothesis that rapid hydrolysis of BCME
 
precludes direct action at tissues beyond the respiratory epithelium.
 
The resulting hydrolysis product (formaldehyde and HCl) are presumably
 
absorbed and distributed throughout the body, but at levels
 




2.2.1.3  Neurological Effects
 
Leong et al. (1981) reported that exposure of male rats to 0.1 ppm
 
for six months did not result in observable histopathology in the
 
nervous system, but no tests of nervous system function were performed.
 
Drew et al. (1975) noted extreme irritability in rats and hamsters
 
exposed 10 to 30 times to 1 ppm of BCME, and concluded that this was
 
evidence of central nervous system effects. However, these symptoms were
 
probably due to treatment-related stress associated with the dis-comfort
 
of BCME exposure. An apparent dose-dependent increase in the frequency
 
of subarachnoid hemorrhage was noted, but the cause of these lesions and
 
the significance were not discussed. As detailed in Section 2.2.1.7
 
(below), nasal tumors of neural cells esthesioneuroepitheliomas) have
 
been noted in rats exposed to 0.1 ppm for 5-6 months (Kuschner et al.
 
1975: Leong et al. 1981).
 
2.2.1.4  Immunological Effects
 
No studies were located regarding immunological effects in humans
 






2.2.1.5  Developmental Effects
 
No studies were located regarding developmental effects in humans
 
or animals following inhalation exposure to BCME.
 
2.2.1.6  Reproductive Effects
 
No studies were located regarding effects on reproductive capacity
 
in humans following inhalation exposure to BCME.
 
Leong et al. (1981) found no histological evidence of injuries to
 
the testes of rats exposed to 0.1 ppm of BCME in air for six months.
 
However, no tests of reproductive function were performed, and rio
 
tests were performed on females.
 
2.2.1.7  Genotoxic Effects
 
No studies were located regarding genotoxic effects in humans
 
following inhalation exposure to BCME. Leong et al. (1981) did not
 
observe any effects on bone marrow chromosomes in rats exposed to 0.1
 
ppm for six months (6 hr/day, 5 days/week). However, the data as
 








A number of case studies and epidemiological studies of
 
occupationally-exposed workers indicate that inhalation of BCME or CME
 
containing BCME is associated with increased risk of lung cancer
 
(Figueroa et al. 1973; Thiess et al. 1973; Sakabe 1973; Albert et al.
 
1975; Weiss and Boucot 1975; DeFonso and Kelton 1976; Lemen et al.
 
1976; Weiss 1976; Pasternack et al. 1977; Reznik et al. 1977; Weiss
 
1982; Roe 1985; Maher and DeFonso 1987; Collingwood et al. 1987). Table
 
2-2 summarizes the data from some of these studies. Although the study
 
populations in these reports were often exposed not only to BCME but to
 
CME and other chemicals as well, the consistent findings strongly
 
support the conclusion that BCME is a lung carcinogen in humans.
 
Although quantitative data on exposure levels were not available,
 
increased risk as a function of exposure duration and/or qualitative
 
estimates of exposure intensity was noted in some cases (DeFonso and
 







carcinomas (Lemen et al. 1976; Figueroa et al. 1973; Weiss et al.
 
1979). Some tumors appeared after only 5 to 10 years of exposure (Weiss
 
and Boucot 1975; Weiss 1976) in young workers (Figueroa et al. 1973;
 
Reznick et al. 1977).
 
A number of studies in animals confirm that BCME is a potent
 
carcinogen with a short latency period. Some of the key data from these
 
studies are summarized in Table 2-3. As shown in the table, levels as
 
low as 0.1 ppm of BCME produce a high incidence (60% to 86%) of
 
respiratory tract tumors in exposed rats, and some tumors developed in
 
animals that had been exposed for periods as short as two weeks
 
(Kuschner et al. 1975; Laskin et al. 1971; Leong et al. 1981). Most of
 
the tumors were nasal tumors, although some lung tumors also developed.
 
Under similar conditions, mice exposed to 0.1 to 1.0 ppm did not
 
develop nasal tumors, but they did have a slight increase in the
 
incidence of mice with pulmonary adenomas (Leong et al. 1981) and in
 
the number of tumors per tumor-bearing mouse (Leong et al. 1971). No
 
increased incidence of nasal tumors or lung adenomas was noted in rats
 
or mice exposed to 0.01 or 0.001 ppm (Leong et al. 1981). Hamsters
 
appear to be more resistant to the carcinogenic effects of BCME than
 
are mice or rats. However, Drew et al. (1975) observed nasal tumors
 
after two years in two hamsters that had been exposed only one to three
 
times to 1.0 ppm BCME. Hamsters exposed for 10 times or more to 1.0 ppm
 
had shortened lifespans, so tumors may not have had time to develop.
 
Based on the evidence reviewed above, EPA has concluded that BCME
 
is a known human carcinogen (EPA Group A). Employing the data of
 
Kuschner et al. (1975), EPA (1988) has calculated an upper bound cancer
 
potency factor (q1*) of 220 (mg/kg/day)
-1. Assuming that a 70-kg adult
 
inhales 20 m3/day, the concentrations of BCME associated with upper
 
bound human risk levels of 10-4, 10-5, 10-6 and l0-7 are 3.4 x l0-7, 3.4 x
 
10-8
, 3.4 x l0-9 and 3.4 x 10-l0 ppm, respectively. These values, and
 








No studies were located regarding acute lethality in humans
 
following oral exposure to BCME. The acute oral LD50 in rats for
 







No studies were located regarding the following effects in humans
 
or animals following oral exposure to BCME:
 
2.2.2.2  Systemic Effects
 
2.2.2.3  Neurological Effects
 
2.2.2.4  Immunological Effects
 
2.2.2.5  Developmental Effects
 
2.2.2.6  Reproductive Effects
 








The estimated LD50 for a single dermal application of undiluted
 
BCME to rabbit skin is 370 mg/kg (Union Carbide 1968). No other
 
estimates of lethal dermal doses were located.
 
2.2.3.2  Systemic Effects
 
Dermal/Ocular Effects.  Because BCME is highly reactive, it is 
directly irritating to skin and other epithelial tissues. Chronic 
(lifetime) application of BCME (1 mg/dose) to the skin of mice produced 
a strong corrosive response, including hair loss, hemorrhagic rash and 
edema of subcutaneous tissue (Van Duuren et al. 1968). In rabbits, a 
single application of undiluted BCME lead to moderate erythema and 
marked necrosis, and a primary dermal irritation score of 6 was 
assigned (Union Carbide 1968). A dose of 5 /µL (7 mg) applied to the 
eye of rabbits produced severe cornea1 necrosis (Union Carbide 1968). 
Other Systemic Effects.  No studies were located regarding
 
respiratory, cardiovascular, gastrointestinal, hematological,
 
musculoskeletal, hepatic or renal effects in humans or animals
 






No studies were located regarding the following effects in humans
 
or animals following dermal exposure to BCME:
 
2.2.3.3  Neurological Effects 
2.2.3.4  Immunological Effects 
2.2.3.5  Developmental Effects 
2.2.3.6  Reproductive Effects 
2.2.3.7  Genotoxic Effects 
2.2.3.8  Cancer 
The first report of the carcinogenicity of BCME was that of Van
 
Duuren et al. (1968). Following dermal exposure (skin painting), BCME
 
was found to produce skin papillomas and carcinomas in over 50% of mice
 
tested after 325 days of treatment. The carcinomas appeared early, with
 
the first appearing after only 196 days of skin application. Subsequent
 
reports confirmed these findings (Van Duuren et al. 1969, 1972; Zajdela
 
et al. 1980). BCME has also been shown to be a skin tumor-initiator.
 
Thus a single skin application of 1 mg of BCME followed by treatment
 
with a known tumor-promoter (phorbol myristate acetate) produced
 
papillomas in a high percentage of treated mice (Van Duuren et al.
 
1968, 1969; Zajdela et al. 1980).
 
2.3  RELEVANCE TO PUBLIC HEALTH
 
Available data indicate that the toxic effects of BCME are
 
restricted to the epithelial tissue where exposure occurs, and this is
 
consistent with the short half-life of BCME in aqueous media. Since
 
exposure is most likely to occur by inhalation, the tissues at greatest
 
risk of injury are those of the respiratory tract. In particular,
 
inhalation of BCME leads to acute irritation, hemorrhage and edema of
 




At present, opportunities for exposure to levels of BCME causing
 
acute lung injury are considered to be remote. However, low levels of
 
exposure may still occur, and these are of concern because of the high
 






in animals following both intermediate and chronic exposure to BCME
 
vapor, and epidemiological studies in exposed workers strongly suggest
 
that BCME causes lung tumors in humans as well. This is supported by
 
the carcinogenic activity of BCME following dermal and parenteral
 
exposure in animals (Gargus et al. 1969; Van Duuren et al. 1968, 1969,
 
1972; Zajdela et al. 1980).
 
An important aspect of the carcinogenicity of BCME is that chronic
 
exposure is not required for tumorigenesis. Respiratory tumors have
 
been noted in rats after as few as 20 exposures, and, although the
 
results are not statistically significant, nasal tumors occurred in a
 
few animals after only one to three exposures. Although no cases of
 
human cancer have been noted after acute exposures, the latency in
 
exposed workers is shorter for BCME than for most other carcinogens,
 
and lung cancer can develop at an early age relative to lung cancer in
 
United States cigarette smokers. In addition, the respiratory tumors
 
produced in humans are predominantly oat-cell carcinomas, a
 
particularly rapid-growing and highly lethal tumor. These observations
 
emphasize the marked carcinogenic hazard of BCME.
 
BCME is a powerful alkylating agent (Van Duuren et al. 1968), and
 
as such would be expected to react readily with DNA and be a powerful
 
genotoxin. However, in vitro tests of mutagenicity have yielded mixed
 
results (Table 2-4), and no effect on bone marrow chromosomes were
 
observed in rats exposed to BCME vapors for six months (Leong et al.
 
1981). Reaction of BCME with DNA in vitro did not affect the melting
 
temperature or the buoyant density of the DNA, nor did it yield
 
isolatable products on reaction with purines or DNA as did other
 
alkylating agents (Van Duuren et al. 1972). These observations suggest
 
that BCME may be hydrolyzed so quickly in an aqueous environment (such
 
as a cell) that interaction with nucleic acids is very limited.
 




The hydrolysis products of BCME are formaldehyde and HCl. Since
 
formaldehyde has been shown to produce nasal tumors in rats (Albert et
 
al. 1982; Sellakumar et al. 1985), it is possible that at least some of
 
the carcinogenic potential of BCME may be due to this degradation
 
product. However, it is apparent from the difference in potency (BCME
 
is much more potent than formaldehyde) that this cannot be the sole
 







formaldehyde and HCl interact synergistically within the cell, but
 
there are no data to clearly support this possibility. Rather, studies
 
by Albert et al. (1982) and Sellakumar et al. (1985) indicate that
 
inhalation exposure of rats to mixtures of formaldehyde and HCl results
 
in little change in the frequency of nasal tumors compared with
 
exposure to formaldehyde alone. However, one animal in this study
 
developed an esthesioneuroepithelioma, a rare kind of tumor which is
 
characteristic of BCME exposure.
 
2.4  LEVELS IN HUMAN TISSUES AND FLUIDS ASSOCIATED WITH HEALTH EFFECTS
 
No studies were located regarding the presence of BCME in human
 
tissues and fluids. It is expected that BCME does not endure in tissues
 
due to its rapid hydrolysis. Measurement of the hydrolysis products
 
(formaldehyde and HCl) is unlikely to be a useful index of exposure,
 
since levels of these products are highly variable due to formation
 
from other sources, and the contribution from BCME would be extremely
 








As previously noted, there are no data available on the levels of
 
BCME or its metabolites in tissues of humans or animals. Although there
 
are a number of epidemiological studies involving occupational exposure
 
to BCME, there are no data on the concentrations of BCME to which
 
workers were exposed. Consequently, there is no information on the
 
relationship between environmental levels of BCME and any health effect
 




No information was located on the toxicokinetics of BCME in
 
animals or humans. It is expected that BCME is rapidly degraded in the
 






2.7  INTERACTIONS WITH OTHER CHEMICALS
 
No information was located regarding interactive effects of BCME
 
with other chemicals that would be relevant to its toxicity. Chemicals
 
of special interest include chloromethyl methyl ether, formaldehyde and
 
HCl, since exposure to BCME frequently occurs along with exposure to
 
CME, and formaldehyde and HCl are formed as BCME decomposes.
 
2.8  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
 
No evidence was located to suggest that any one group of humans
 
are more susceptible to BCME than another. Since no data are available
 
on pharmacokinetics or mechanisms of action, it is not possible to
 
predict populations that might be unusually susceptible to BCME on the
 
basis of genetic traits or health status.
 
2.9  ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA, directs the Administrator of ATSDR
 
(in consultation with the Administrator of EPA and agencies and
 
programs of the Public Health Service) to assess whether adequate
 
information on the health effects of BCME is available. Where adequate
 
information is not available, ATSDR, in cooperation with the National
 
Toxicology Program (NTP), is required to assure the initiation of a
 
program of research designed to determine these health effects (and
 
techniques for developing methods to determine such health effects).
 
The following discussion highlights the availability, or absence, of
 
exposure and toxicity information applicable to human health
 
assessment. A statement of the relevance of identified data needs is
 
also included. In a separate effort, ATSDR, in collaboration with NTP
 




2.9.1  Existing Information on Health Effects of BCME
 
As shown in Figure 2-2, no data exist on the effects of BCME in
 
humans, except for data on lung cancer risk following inhalation
 
exposure. In animals, there are limited data on the effects of
 
inhalation exposure, but only one observation is available for oral
 
exposure (an estimate of the oral LD50). This is probably not a major
 







limited data on dermal lethality and direct dermal and ocular
 
irritation, but none on any systemic effects following dermal exposure.
 
Most research has focused on the carcinogenic effects of inhaled BCME,
 
since this is the most common route of human exposure.
 
2.9.2  Data Needs
 
Single Dose Exposure. Several studies have been performed in
 
animals on the effects of single inhalation exposures to BCME, and
 
exposure conditions leading to acute lethality are reasonably well
 
defined. However, the acute does-response curve for sub- lethal effects
 
on the lung has not been determined, and further studies to identify
 
the acute NOAEL would be valuable. Due to the rapid hydrolysis of BCME,
 
effects are not likely to occur in nonepithelial tissues, but careful
 
studies to investigate this would still be appropriate.
 
Repeated Dose Exposure.  Available studies on the effects of
 
repeated inhalation exposure of animals to BCME (Leong et al. 1971,
 
1981) indicate that an exposure level of 0.1 ppm is a NOAEL for most
 
systemic effects in rats, while 1.0 ppm leads to significant injury to
 
lung in mice. Further studies to confirm these estimates and to
 
determine both NOAEL and LOAEL values in each species would be useful
 
in the protection of occupationally exposed workers.
 
Chronic Exposure and Carcinogenicity.  A number of studies in
 
animals indicate that inhalation of BCME is associated with risk of
 
nasal or lung tumors. In order to assess the potential risks in the
 
workplace, further studies in animals might be helpful in improving
 
information on the dose and time-dependency of BCME-induced
 
tumorigenesis. In particular, studies would be valuable to investigate
 
why BCME induces tumors with such a short latency, and why it results
 
in nasal tumors in some species and lung tumors in others. Studies on
 
the interaction of BCME with other chemicals such as CME (with which it
 
is often associated in the workplace) would also be valuable.
 
Genotoxicity. The genotoxicity of BCME has been investigated in
 
several strains of bacteria but such systems may not be optimal for
 
investigating the effects of such a rapidly hydrolyzed material.
 
Specifically, if BCME acts as an alkylating agent to damage DNA, then
 






yield misleading results. Tests in prokaryotic and eukaryotic systems
 
designed to minimize the degree of hydrolysis in the medium prior to
 
cell penetration would be valuable in estimating the potential
 
genotoxic effect of BCME on the respiratory epithelium.
 
Reproductive Toxicity.  Only one study, Leong et al. (1981), was
 
located which addressed the toxic effects of BCME on reproductive
 
organs. This study examined the histological appearance of reproductive
 
tissues in male rats only, and no test of reproductive function was
 
performed. No studies were located on reproductive effects in females.
 
On this basis, more extensive tests of BCME exposure on reproductive
 
function in both male and female animals would be valuable in
 




Developmental Toxicity.  No studies were located on the
 
developmental toxicity of BCME. Although the rapid hydrolysis of BCME
 
makes it unlikely that BCME could act on the fetus directly, effects
 
might still occur as a consequence of maternal toxicity.
 
Immunotoxicity. No studies were located on the effects of BCME
 
exposure on the immune system. Because the immune system is often
 
observed to be especially sensitive to chemical toxicants,
 




Neurotoxicity.  Drew et al. (1975) reported that inhalation
 
exposure of rats and hamsters lead to subarachnoid hemorrhage, but the
 
severity or significance of this finding was not discussed. These
 
limited data suggest that a more thorough study of the affects of BCME
 
on the nervous system would be useful, including tests both of
 




Epidemiological and Human Dosimetry Studies.  A number of
 
epidemiological studies have been performed on workers exposed to BCME
 
in the past. While these studies are limited by the absence of reliable
 
dosimetry data and the presence of other risk factors (smoking, other
 
chemicals), the data nevertheless constitute strong evidence that BCME
 






epidemiological studies may not be feasible since exposure to BCME in
 
the workplace is now so limited, continued follow-up of populations
 
exposed in the past will be helpful in refining estimates of the
 
latency and the incidence of cancer in these cohorts.
 
Biomarkers of Disease. No biomarkers are known that are
 
specific for BCME-induced lung injury. Standard chemical examination of
 
nose and throat can provide an index of local irritation, and
 
examination of sputum for abnormal cell types can provide information
 
on the state of the respiratory epithelium. However, these tests cannot
 
distinguish BCME-induced effects from effects caused by smoking or
 
exposure to other chemicals, and can only discover changes after damage
 
to the tissue has already occurred. Continued efforts to devise more
 
sensitive and more specific early biomarkers of disease (especially
 
lung cancer) would be valuable.
 
Disease Registries.  There is no registry of humans with
 
BCMEinduced disease. The identities of individuals who have died from
 
lung cancer (particularly oat cell carcinoma) can be found by searching
 
death certificates, but it is expected that only a small fraction of
 
all such cases would be related to BCME exposure. Creation of a disease
 
registry for BCME would be valuable in helping to establish a clearer
 
understanding of the association between BCME exposure and lung cancer.
 
Bioavailability from Environmental Media. No studies were
 
located on bioavailability of BCME in environmental media. However,
 
this is not a significant limitation, since BCME is not expected to
 
occur in significant quantities in any medium except air.
 
Food Chain Bioaccumulations.  No studies were located on food
 
chain bioaccumulation of BCME. This is not a significant limitation,
 
however, since it is expected that BCME is rapidly hydrolyzed in living
 
organisms and will not bioaccumulate.
 
Absorption, Distribution, Metabolism, and Excretion.  No studies were
 
located on the toxicokinetics of BCME in animals or humans. Although
 
acquisition of such data is made difficult by the rapid hydrolysis of
 
BCME, studies focusing on the rate of entry of BCME into epithelial
 
cells, the half-time for hydrolysis in the tissue environment, the fate
 
of the degradation products, and interaction with DNA, if any, would be
 






Comparative Toxicokinetics.  No studies were located on the
 
toxicokinetics of BCME in different species. Such studies might be
 
helpful in understanding the differences that have been observed
 
between species with respect to carcinogenic potency and tissue
 
specificity (see Table 2-3).
 
2.9.3  Ongoing Studies
 
No information was located regarding ongoing research on the
 




3. CHEMICAL AND PHYSICAL INFORMATION
 
3.1  CHEMICAL IDENTITY
 
Table 3-1 lists common synonyms, trade names and other pertinent
 
identification information for BCME.
 
3.2  PHYSICAL AND CHEMICAL PROPERTIES
 













Production of BCME in this country was curtailed in 1974 following
 
stringent regulation by the Occupational Safety and Health
 
Administration (EPA 1979; OSHA 1974). Available information indicates
 
that BCME is no longer produced for sale in the United States (EPA
 
1980a; USITC 1987; HSDB 1988), although at least one facility
 
manufactures BCME as a non-isolated, site-limited intermediate used in
 
the production of other chemicals (Brothers 1989; Ress 1977). BCME is
 
produced as a contaminant during the manufacture of chloromethyl methyl
 










In the past, BCME was used for crosslinking of cellulose,
 
preparation of styrene and other polymers, surface treatment of
 
vulcanized rubber to increase adhesion, and in the manufacture of
 
flameretardant fabrics (EPA 1980a). These applications have been
 






Any products, residues or container liners contaminated with BCME
 
are considered acute hazardous waste under the Resource Conservation
 
and Recovery Act (RCRA) (40 CFR 261.33 (c)), and must be disposed of by
 
transport to a RCRA waste storage and disposal facility. The preferred
 
method of disposal is incineration (OSHA 1974; Sittig 1985).
 
4.5  ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA, directs the Administrator of ATSDR
 
(in consultation with the Administrator of EPA and agencies and
 
programs of the Public Health Service) to assess whether adequate
 
information on the health effects of BCME is available. Where adequate
 
information is not available, ATSDR, in cooperation with the National
 






4. PRODUCTION, IMPORT, USE AND DISPOSAL
 
designed to determine these health effects (and techniques for
 
developing methods to determine such health effects). The following
 
discussion highlights the availability, or absence, of exposure and
 
toxicity information applicable to human health assessment. A statement
 
of the relevance of identified data needs is also included. In a
 
separate effort,ATSDR, in collaboration with NTP and EPA, will
 
prioritize data needs across chemicals that have been profiled.
 
4.5.1  Data Needs
 
Production, Import, Use and Disposal.  Although BCME is not
 
produced as a commercial product in the United States, available
 
information indicates that small quantities are produced and used in
 
captive processes within at least one chemical factory. Determination
 
of the amounts involved and whether BCME is used at other locations
 
would be useful in evaluating whether risk of BCME exposure from
 
current industrial practices remains of concern. In addition,
 
compilation of data on typical contaminant levels of BCME currently
 
found in other products such as CME would be helpful in determining
 
whether or not this is a source of concern.
 




of 1986 (EPCRTKA), (§313), (Pub. L. 99-499, Title III, §313),
 
industries are required to submit release information to the EPA. The
 
Toxic Release Inventory (TRI), which contains release information for
 
1987, became available in May of 1989. This database will be updated
 












Because BCME is not currently used as an isolated material in this
 
country, and because it is rapidly degraded in the environment, the
 
probability of human exposure to BCME is low. The most likely means of
 
exposure is inhalation of BCME vapors in the workplace during the
 
production and use of chemicals such as CME, in which BCME may occur as
 
a contaminant or be formed inadvertently. Inhalation of BCME in ambient
 
air might also occur near such a facility, but there is no evidence
 
that this occurs. Exposure through other media (water, food, soil) is
 
unlikely to be significant.
 
5.2  RELEASES TO THE ENVIRONMENT
 
No information was located on the amount of BCME released to air,
 
water or soil. Because BCME is readily volatile at room temperature,
 
emissions into the atmosphere could occur, but OSHA regulations require
 
that processes involving BCME be contained (OSHA 1974). Releases into
 
water could occur but would be of little significance, due to the rapid
 
hydrolysis of BCME in water.
 
5.3  ENVIRONMENTAL FATE
 
5.3.1  Transport and Partitioning
 
No information was located on the transport and partitioning of
 
BCME in the environment. Due to the relatively short half-life in both
 
air and water, it is unlikely that significant transport or
 
partitioning between media occurs.
 




The primary process for BCME degradation in air is believed to be
 
reaction with photochemically-generated hydroxyl radicals,. Reaction
 
products are believed to include chloromethyl formate, ClHCO,
 
formaldehyde and HCl (Cupitt 1980; EPA 1987a). The atmospheric halflife
 




5. POTENTIAL FOR HUMAN EXPOSURE
 
1.36 hours. Hydrolysis in the vapor phase is slower, with an estimated
 
half-life of 25 hours in moist air (80% relative humidity at 25°C) (Tou
 
and Kallos 1974). Reaction of BCME with molecular oxygen may also
 
occur, but the rate of this reaction is not known. Other calculations
 
suggest an atmospheric residence time of 0.2 to 2.9 days (Cupitt 1980).
 
Although hydrolysis of BCME to formaldehyde and HCl is highly
 
favored thermodynamically, low levels of BCME may form by the reverse
 
reaction when high concentrations of formaldehyde and HCl are mixed.
 
Frankel et al. (1974) studied this reaction, and found that although
 
BCME levels increased exponentially in proportion to reactant
 
concentrations, yields were only 0.002 to 0.01 mol% at reactant
 
concentrations ranging from 20 to 1,000 ppm. For example, the BCME
 
concentration was 3 ppb in a mixture of 100 ppm formaldehyde and 100
 
ppm HCl. Based on the data of Frankel et al. (1974), Travenius (1982)
 
proposed the empirical equation:
 
log(BCME) -2.25 + 0.67• log(HCHO) + 0.77• log(HCl)ppb = ppm ppm
 
Employing this equation, the concentration of BCME likely to form from
 
any mixture of formaldehyde and HCl may be calculated. In the
 
workplace, assuming that exposure occurred at the Threshold Limit
 
Values for each (1 ppm for formaldehyde and 5 ppm for HCl), the
 
resulting BCME concentration would be 0.02 ppb. Concentrations in the
 
home and the ambient environment are likely to be significantly lower
 
for one or both reactants, and concentrations of BCME would be expected
 




BCME is rapidly hydrolyzed in water to yield formaldehyde and HCl,
 
with a hydrolysis rate constant of 0.018 sec-1 at 20°C (Tou et al.
 
1974). This corresponds to a half-life of approximately 38 seconds.
 
Under laboratory conditions (a sealed vessel from which formaldehyde
 
and HCl cannot escape), an equilibrium is established in which about
 
80% of the BCME is rapidly hydrolyzed, with about 20% of the BCME
 
remaining (Van Duuren et al. 1972). In the environment, formaldehyde
 
and HCl formed by hydrolysis of BCME would be expected to dissipate by
 










No information was located on the fate of BCME in soil. However,
 
it is probable that BCME would rapidly hydrolyze upon contact with
 
moisture in soil or would react with soil constituents. Consequently,
 








BCME has not been detected in ambient air. Some early reported
 
industrial air concentrations ranged from 0.7 to 5.2 ppm, but increased
 
care in the handling of this compound has reduced workplace levels to
 
the sub-ppb range (NIOSH 1972a). No other quantitative data on BCME
 




BCME has not been detected in ambient waters, but has been
 
reported to be present in groundwater at one chemical waste site being
 
investigated under Superfund (CLPSD 1988). Because BCME hydrolyzes so
 




BCME was reported to be present at 0.5% of the waste sites being
 
investigated under Superfund (CLPSD 1988), but quantitative data were
 
not available. As with the data regarding occurrence in water, these
 
data must be considered with caution, since BCME is unlikely to endure
 
at measurable levels in soil.
 
5.4.4  Other Media
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5.5  GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
 
The most likely route of human exposure to BCME is by inhalation,
 
but available data are not adequate to estimate typical dose levels.
 
Doses are'likely to be close to zero for the general population, but
 
could be of concern inside or close by industrial sites where
 
chloromethylation processes occur (Roe 1985).
 
5.6  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
 
As discussed above, the individuals most likely to have potential
 
exposure to BCME are industrial workers who manufacture or use
 
chemicals such as CME that might contain BCME as a contaminant. The
 
possibility exists that residents near a facility or a waste site that
 
permits escape of BCME could also be exposed, but there are no data to
 
establish whether or not this occurs or is of concern.
 
5.7  ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA, directs the Administrator of ATSDR
 
(in consultation with the Administrator of EPA and agencies and
 
programs of the Public Health Service) to assess whether adequate
 
information on the health effects of BCME is available. Where adequate
 
information is not available, ATSDR, in cooperation with the National
 
Toxicology Program (NTP), is required to assure the initiation of a
 
program of research designed to determine these health effects (and
 
techniques for developing methods to determine such health effects).
 
The following discussion highlights the availability, or absence, of
 
exposure and toxicity information applicable to human health
 
assessment. A statement of the relevance of identified data needs is
 
also included. In a separate effort, ATSDR, in collaboration with NTP
 




5.7.1  Data Needs
 
Physical and Chemical Properties.  The physical and chemical
 
properties most important in evaluating the environmental fate of BCME
 
have been determined (see Table 3-2). Although some of these values
 
(eg, solubility in water) are calculated, this is not a significant
 
limitation, and additional studies on the physical or chemical
 




5. POTENTIAL FOR HUMAN EXPOSURE
 
Environmental Fate.  Available data make it clear that BCME is not
 
likely to endure in the environment. No further studies appear to be
 
required on fate in water or other moist media (food, soil), since the
 
principal fate is rapid hydrolysis. Additional studies on the kinetics
 
of BCME destruction in air by oxidation and hydrolysis would be
 
valuable in refining mathematical models used to calculate levels of
 
BCME in air around a point source.
 
Exposure Levels in Environmental Media.  Information on the
 
occurrence of BCME in environmental media is very limited. No
 
information was located on levels in ambient air, water or soil. BCME
 
has been reported to occur in water or soil near a few waste sites, but
 
these findings may not be reliable. Because of the instability of BCME
 
in water and soil, further efforts to measure BCME in these media are
 
unlikely to produce useful information. However, the volatility and
 
atmospheric lifetime of BCME are such that monitoring air for BCME in
 
the vicinity of waste sites, industrial facilities or other possible
 
sources could provide valuable information on the occurrence of this
 
chemical in the environment.
 
Exposure Levels in Humans. No data exists on present-day exposure
 
levels of humans to BCME. Exposure is likely to be close to zero for
 
the general public. However, because BCME is such at potent carcinogen,
 
even low levels of exposure are of potential concern, and additional
 
data on exposure levels in the workplace and in the environment near
 
waste sites would be valuable.
 
Exposure Registries.  No exposure registries exist for humans
 
exposed to BCME. Although the exposed population is likely to be quite
 
small, creation of such a registry would provide the opportunity to
 
obtain valuable additional data on the health effects of BCME.
 
5.7.2  Ongoing Studies
 
No information was located regarding any ongoing studies on the
 









6.1  BIOLOGICAL MATERIALS
 
There is little need or opportunity to measure BCME in biological
 
samples because of its rapid hydrolysis in water to yield formaldehyde
 
and chloride. The abundance of chloride and, to a lesser extent, of
 
formaldehyde, in biological materials precludes use of these hydrolysis
 
products as an index of exposure to BCME. Therefore, the analysis of
 
BCME in biological samples from exposed humans is virtually impossible.
 
6.2  ENVIRONMENTAL SAMPLES
 
Methods for the determination of BCME in environmental samples are
 
currently confined to monitoring of air. It is possible, to monitor
 
BCME in air at extremely low levels, and several analytical methods
 
have detection limits of a few tenths of a ppb. Most methods for the
 
analysis of BCME in air call for collecting samples on a solid
 
adsorbent, followed by thermal desorption and gas chromatographic
 
analysis. A typical procedure (ASTM 1987) uses a sampling tube packed
 
with Chromosorb 101 adsorbent through which up to 25 L of air can be
 
drawn for a period as long as 24 hours. For analyte determination, the
 
sampling tube is attached to a gas chromatograph so that carrier gas
 
can be passed through it and through the analytical column. With the
 
carrier gas flowing, the collection column is heated to 150°C for four
 
minutes and the analyte flows onto the analytical column, which is
 
maintained at room temperature. Following desorption of the BCME, the
 
analytical column is heated to 130°C with a programmed temperature
 




It has been noted (Travenius 1982) that common adsorption methods
 
of sampling BCME from air are prone to giving inaccurate results
 
because of hydrolysis of the analyte by coadsorbed water. For this
 
reason, most procedures for methods involving collection of BCME on
 
solid adsorbents require that samples in collection tubes be processed
 
within a few days and protected from humidity.
 







6.3  ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA, directs the Administrator of ATSDR
 
(in consultation with the Administrator of EPA and agencies and
 
programs of the Public Health Service) to assess whether adequate
 
information on the health effects of BCME is available. Where adequate
 
information is not available, ATSDR, in cooperation with the National
 
Toxicology Program (NTP), is required to assure the initiation of a
 
program of research designed to determine these health effects (and
 
techniques for developing methods to determine such health effects).
 
The following discussion highlights the availability, or absence, of
 
exposure and toxicity information applicable to human health
 
assessment. A statement of the relevance of identified data needs is
 
also included. In a separate effort, ATSDR, in collaboration with NTP
 




6.3.1  Data Needs
 
Methods for Determining Parent Compound and Metabolites in
 
Biological Materials. No methods were located for determining BCME
 
in biological samples. It does not appear that this is a significant
 
limitation, however, since BCME is not expected to endure in tissues or
 
fluids. Although there are adequate methods for the detection of
 
formaldehyde and chloride, these are not likely to be useful for
 
assessing exposure to BCME, since any change in the levels of these
 
compounds would be well within normal biological variability.
 
Methods for Biomarkers of Exposure. No methods were located for
 
measuring any biomarkers of exposure to BCME. Although covalent adducts
 
of BCME with cellular proteins or DNA have not yet been reported,
 
development of sensitive and specific immunological assays for such
 
adducts would provide a valuable means of detecting and perhaps
 
quantifying human exposure levels.
 
Methods for Determining Parent Compound and Degradation Products
 
in Environmental Media. Air is the only environmental medium
 
susceptibleto significant contamination by BCME and methods for the
 
determination of this compound in air are straightforward. The greatest
 








that enable its efficient collection from large volumes of air without
 
hydrolysis during collection or storage. Since health concern might
 
extend to concentrations well below 1 ppb, improvement in sensitivity
 
would also be valuable.
 
6.3.2  Ongoing Studies
 
Because of evidence that BCME is carcinogenic even at very low
 
levels in the atmosphere, current studies of its analysis are
 
concentrating on extending the detection limit to even lower levels.
 
Because of its chlorine content, BCME can be measured with extreme
 
sensitivity by electron capture detection after gas chromatographic
 
separation of this analyte. Efforts are underway by Dr. Robert Sievers
 
(University of Colorado, Boulder) to improve collection methods that
 
meet the criteria of (1) highly efficient collection of BCME at sub-ppb
 
levels in air, (2) no loss of analyte from hydrolysis resulting from
 
atmospheric humidity, and (3) rapid, efficient, nondestructive
 




7. REGULATIONS AND ADVISORY STANDARDS
 
Because of its potential to cause adverse health effects in
 
exposed people, a number of regulations and advisory values have been
 
established for BCME by various international, national and state
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Acute Exposure -- Exposure to a chemical for a duration of 14 days or
 
less, as specified in the Toxicological Profiles.
 
Adsorption Coefficient (KOC) -- The ratio of the amount of a chemical
 
adsorbed per unit weight of organic carbon in the soil or sediment to
 
the concentration of the chemical in solution at equilibrium.
 
Adsorption Ratio (Kd) -- The amount of a chemical adsorbed by a
 
sediment or soil (i.e., the solid phase) divided by the amount of
 
chemical in the solution phase, which is in equilibrium with the solid
 
phase, at a fixed solid/solution ratio. It is generally expressed in
 
micrograms of chemical sorbed per gram of soil or sediment.
 
Bioconcentration Factor (BCF) -- The quotient of the concentration of a
 
chemical in aquatic organisms at a specific time or during a discrete
 
time period of exposure divided by the concentration in the surrounding
 
water at the same time or during the same time period.
 
Cancer Effect Level (CEL) -- The lowest dose of chemical in a study or
 
group of studies which produces significant increases in incidence of
 




Carcinogen -- A chemical capable of inducing cancer.
 




Chronic Exposure -- Exposure to a chemical for 365 days or more, as
 
specified in the Toxicological Profiles.
 
Developmental Toxicity -- The occurrence of adverse effects on the
 
developing organism that may result from exposure to a chemical prior
 
to conception (either parent), during prenatal development, or
 
postnatally to the time of sexual maturation. Adverse developmental
 






Embryotoxicity and Fetotoxicity -- Any toxic effect on the conceptus as
 
a result of prenatal exposure to a chemical; the distinguishing feature
 
between the two terms is the stage of development during which the
 
insult occurred. The terms, as used here, include malformations and
 
variations, altered growth, and in utero death.
 
EPA Health Advisory -- An estimate of acceptable drinking water levels
 
for a chemical substance based on health effects information. A health
 
advisory is not a legally enforceable federal standard, but serves as
 
technical guidance to assist federal, state, and local officials.
 
Immediately Dangerous to Life or Health (IDLH) -- The maximum
 
environmental concentration of a contaminant from which one could
 




Intermediate Exposure -- Exposure to a chemical for a duration of 15­
364 days, as specified in the Toxicological Profiles.
 
Immunologic Toxicity -- The occurrence of adverse effects on the immune
 




In vitro -- Isolated from the living organism and artificially
 
maintained, as in a test tube.
 
In vivo -- Occurring within the living organism.
 
Lethal Concentration  (LC ) -- The lowest concentration of a
(L0) LO





Lethal Concentration  (LC ) -- A calculated concentration of a
(50) 50

chemical in air to which exposure for a specific length of time is
 




Lethal Dose(L0) (LD LO) -- The lowest dose of a chemical introduced by a
 








Lethal Dose  (LD ) -- The dose of a chemical which has been
(50) 50





Lowest-Observed-Adverse-Effect Level (LOAEL) -- The lowest dose of
 
chemical in a study or group of studies which produces statistically or
 
biologically significant increases in frequency or severity of adverse
 
effects between the exposed population and its appropriate control.
 
LT50 (lethal time) -- A calculated period of time within which a
 
specific concentration of a chemical is expected to cause death in 50%
 
of a defined experimental animal population.
 
Malformations -- Permanent structural changes that may adversely affect
 
survival, development, or function.
 
Minimal Risk Level -- An estimate of daily human exposure to a chemical
 
that is likely to be without an appreciable risk of deleterious effects
 
(noncancerous) over a specified duration of exposure.
 
Mutagen -- A substance that causes mutations. A mutation is a change in
 
the genetic material in a body cell. Mutations can lead to birth
 
defects, miscarriages, or cancer.
 
Neurotoxicity -- The occurrence of adverse effects on the nervous
 
system following exposure to a chemical.
 
No-Observed-Adverse-Effect Level (NOAEL) -- That dose of chemical at
 
which there are no statistically or biologically significant increases
 
in frequency or severity of adverse effects seen between the exposed
 
population and its appropriate control. Effects may be produced at this
 
dose, but they are not considered to be adverse.
 
Octanol-Water Partition Coefficient (KOW) -- The equilibrium ratio of
 




Permissible Exposure Limit (PEL) -- An allowable exposure level in
 






q1* -- The upper-bound estimate of the low-dose slope of the 
doseresponse 
curve as determined by the multistage procedure. The q1* can be used to 
calculate an estimate of carcinogenic potency, the incremental excess 
cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for 
food, and µg/m3 for air). 
Reference Dose (RfD) -- An estimate (with uncertainty spanning perhaps
 
an order of magnitude) of the daily exposure of the human population to
 
a potential hazard that is likely to be without risk of deleterious
 
effects during a lifetime. The RfD is operationally derived from the
 
NOAEL (from animal and human studies) by a consistent application of
 
uncertainty factors that reflect various types of data used to estimate
 
RfDs and an additional modifying factor, which is based on a
 
professional judgment of the entire database on the chemical. The RfDs
 
are not applicable to nonthreshold effects such as cancer.
 
Reportable Quantity (RQ) -- The quantity of a hazardous substance that
 
is considered reportable under CERCLA. Reportable quantities are: (1) 1
 
lb or greater or (2) for selected substances, an amount established by
 
regulation either under CERCLA or under Sect. 311 of the Clean Water
 
Act. Quantities are measured over a 24-h period.
 
Reproductive Toxicity -- The occurrence of adverse effects on the
 
reproductive system that may result from exposure to a chemical. The
 
toxicity may be directed to the reproductive organs and/or the related
 
endocrine system. The manifestation of such toxicity may be noted as
 
alterations in sexual behavior, fertility, pregnancy outcomes, or
 




Short-Term Exposure Limit (STEL) -- The maximum concentration to which
 
workers can be exposed for up to 15 min continually. No more than four
 
excursions are allowed per day, and there must be at least 60 min
 
between exposure periods. The daily TLV-TWA may not be exceeded.
 
Target Organ Toxicity -- This term covers a broad range of adverse
 
effects on target organs or physiological systems (e.g., renal,
 
cardiovascular) extending from those arising through a single limited
 






TD50 (toxic dose) -- A calculated dose of a chemical, introduced by a
 
route other than inhalation, which is expected to cause a specific
 
toxic effect in 50% of a defined experimental animal population.
 
Teratogen -- A chemical that causes structural defects that affect the
 
development of an organism.
 
Threshold Limit Value (TLV) -- A concentration of a substance to which
 
most workers can be exposed without adverse effect. The TLV may be
 
expressed as a TWA, as a STEL, or as a CL.
 
Time-weighted Average (TWA) -- An allowable exposure concentration
 
averaged over a normal 8-h workday or 40-h workweek.
 
Uncertainty Factor (UF) -- A factor used in operationally deriving the
 
RfD from experimental data. UFs are intended to account for (1) the
 
variation in sensitivity among the members of the human population, (2)
 
the uncertainty in extrapolating animal data to the case of humans, (3)
 
the uncertainty in extrapolating from data obtained in a study that is
 
of less than lifetime exposure, and (4) the uncertainty in using LOAEL
 









A peer review panel was assembled for BCME. The panel consisted of
 
the following members: Dr. Douglas Arnold, Toxicologist, Banting
 
Research Center, Health and Welfare, Canada; Dr. James Bruckner,
 
Director, Toxicology Programs, Department of Pharmacology and
 
Toxicology, University of Georgia; Dr. Chon Shoaf, Research Associate,
 
Duke University Medical Center; Dr. Dietrich Hoffman, Associate
 
Director, American Health Foundation, Valhalla, NY; and Dr. Benjamin
 
Van Duuren, Professor of Environmental Medicine, New York University
 
Medical Center. These experts collectively have knowledge of BCME's
 
physical and chemical properties, toxicokinetics, key health end
 
points, mechanisms of action, human and animal exposure, and
 
quantification of risk to humans. All reviewers were selected in
 
conformity with the conditions for peer review specified in the
 
Superfund Amendments and Reauthorization Act of 1986, Section 110.
 
A joint panel of scientists from ATSDR and EPA has reviewed the
 
peer reviewers' comments and determined which comments will be included
 
in the profile. A listing of the peer reviewers' comments not
 
incorporated in the profile, with a brief explanation of the rationale
 
for their exclusion, exists as part of the administrative record for
 
this compound. A list of databases reviewed and a list of unpublished
 
documents cited are also included in the administrative record.
 
The citation of the peer review panel should not be understood to
 
imply their approval of the profile's final content. The responsibility
 
for the content of this profile lies with the Agency for Toxic
 
Substances and Disease Registry.
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